Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
Louisville Metabolic and Atherosclerosis Research Center · Regeneron (United States) · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
578
total citations
- FWCI
- 89.69
- Percentile
- 100%
- References
- 21
Citations per year
Authors
8Topics & keywords
Topics
Keywords
- PCSK9
- Ezetimibe
- Medicine
- Evolocumab
- Alirocumab
- Placebo
- Internal medicine
- Statin
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.